Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.

Hiroaki YaoiYasuaki ShidaTakehisa KitazawaMidori Shima Keiji Nogami

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

Emicizumab-induced enhancing effects of thrombus formation, independent on VWF, may be useful as an alternative therapy for type 2A VWD patients. These results supported a critical role for the FVIII-VWF complex facilitating thrombus formation under high shear.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
patient reported outcomes
diabetic rats
patient reported